Cargando…

Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen

SIMPLE SUMMARY: The aims of this study were to investigate aminopeptidase expression in multiple myeloma and to identify the aminopeptidases responsible for the activation of the peptide–drug conjugate melflufen in multiple myeloma. We observed a differential expression of aminopeptidases between re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miettinen, Juho J., Kumari, Romika, Traustadottir, Gunnhildur Asta, Huppunen, Maiju-Emilia, Sergeev, Philipp, Majumder, Muntasir M., Schepsky, Alexander, Gudjonsson, Thorarinn, Lievonen, Juha, Bazou, Despina, Dowling, Paul, O`Gorman, Peter, Slipicevic, Ana, Anttila, Pekka, Silvennoinen, Raija, Nupponen, Nina N., Lehmann, Fredrik, Heckman, Caroline A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036322/ https://www.ncbi.nlm.nih.gov/pubmed/33810334 http://dx.doi.org/10.3390/cancers13071527

Ejemplares similares

Melflufen, a peptide‐conjugated alkylator, is an efficient anti‐neo‐plastic drug in breast cancer cell lines
por: Schepsky, Alexander, et al.
Publicado: (2020)

PB2071: SENSITIVITY OF MULTIPLE MYELOMA TO MELFLUFEN ASSOCIATES WITH DECREASED P53 ACTIVITY AND ENRICHMENT OF DNA DAMAGE REPAIR PATHWAY GENES
por: Miettinen, Juho, et al.
Publicado: (2023)

Prognostic significance of esterase gene expression in multiple myeloma
por: Kumari, Romika, et al.
Publicado: (2021)

The Peptide–Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death
por: Flanagan, Ken, et al.
Publicado: (2022)

S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma
por: Liu, Minxia, et al.
Publicado: (2021)

Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen
por: Gebraad, Arjen, et al.
Publicado: (2022)

Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients
por: Tierney, Ciara, et al.
Publicado: (2021)

Cellular Plasticity and Heterotypic Interactions during Breast Morphogenesis and Cancer Initiation
por: Ingthorsson, Saevar, et al.
Publicado: (2022)

A germline exome analysis reveals harmful POT1 variants in multiple myeloma patients and families
por: Hakkarainen, Marja, et al.
Publicado: (2022)

Peroxidasin Enhances Basal Phenotype and Inhibits Branching Morphogenesis in Breast Epithelial Progenitor Cell Line D492
por: Sigurdardottir, Anna Karen, et al.
Publicado: (2021)

Correction to: Peroxidasin Enhances Basal Phenotype and Inhibits Branching Morphogenesis in Breast Epithelial Progenitor Cell Line D492
por: Sigurdardottir, Anna Karen, et al.
Publicado: (2022)

Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing
por: Majumder, Muntasir Mamun, et al.
Publicado: (2017)

YKL-40/CHI3L1 facilitates migration and invasion in HER2 overexpressing breast epithelial progenitor cells and generates a niche for capillary-like network formation
por: Morera, Erika, et al.
Publicado: (2019)

P874: DECIPHERING PLASMA CELL HETEROGENEITY AND TUMOR MICROENVIRONMENT IN LIGHT-CHAIN AMYLOIDOSIS USING SINGLE CELL RNA-SEQUENCING
por: Srivastava, A., et al.
Publicado: (2022)

Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted Approaches
por: Dowling, Paul, et al.
Publicado: (2021)

Proteomic and Metabolomic Analysis of Bone Marrow and Plasma from Patients with Extramedullary Multiple Myeloma Identifies Distinct Protein and Metabolite Signatures
por: Dunphy, Katie, et al.
Publicado: (2023)

Expression of ncRNAs on the DLK1-DIO3 Locus Is Associated With Basal and Mesenchymal Phenotype in Breast Epithelial Progenitor Cells
por: Budkova, Zuzana, et al.
Publicado: (2020)

Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells
por: Byrgazov, Konstantin, et al.
Publicado: (2021)

In vitro and in vivo activity of melflufen (J1)in lymphoma
por: Delforoush, Maryam, et al.
Publicado: (2016)

Preclinical activity of melflufen (J1) in ovarian cancer
por: Carlier, Charlotte, et al.
Publicado: (2016)

The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma
por: McCurdy, Arleigh, et al.
Publicado: (2022)

Unraveling the Breast: Advances in Mammary Biology and Cancer Methods
por: Monkkonen, Teresa, et al.
Publicado: (2021)

Deep Immune Profiling of Multiple Myeloma at Diagnosis and under Lenalidomide Maintenance Therapy
por: Luoma, Sini, et al.
Publicado: (2023)

Melflufen - a peptidase-potentiated alkylating agent in clinical trials
por: Wickström, Malin, et al.
Publicado: (2017)

Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma
por: Mateos, María-Victoria, et al.
Publicado: (2020)

The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.
por: Olivier, Timothée, et al.
Publicado: (2022)

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
por: Richardson, Paul G., et al.
Publicado: (2021)

Comorbidity characteristics of multiple myeloma patients diagnosed in Finland 2005–2016
por: Toppila, Iiro, et al.
Publicado: (2022)

Authors’ reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA
por: Schjesvold, Fredrik H, et al.
Publicado: (2022)

Twelfth Annual ENBDC Workshop: Methods in Mammary Gland Biology and Breast Cancer
por: Charifou, Elsa, et al.
Publicado: (2021)

In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia
por: Strese, Sara, et al.
Publicado: (2016)

Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor
por: Sgherza, Nicola, et al.
Publicado: (2021)

P426: HDAC INHIBITORS RESTORE SENSITIVITY TO VENETOCLAX AND NAVITOCLAX IN AML CELLS RESULTING IN THE IRREVERSIBLE DNA DAMAGE
por: Khabusheva, Elmira, et al.
Publicado: (2023)

Aminopeptidases
por: Sanz, Yolanda
Publicado: (2007)

Preadipocytes proliferate and differentiate under the guidance of Delta-like 1 homolog (DLK1)
por: Traustadottir, Gunnhildur Asta, et al.
Publicado: (2013)

Phosphonic Acid Analogues of Phenylglycine as Inhibitors of Aminopeptidases: Comparison of Porcine Aminopeptidase N, Bovine Leucine Aminopeptidase, Tomato Acidic Leucine Aminopeptidase and Aminopeptidase from Barley Seeds
por: Wanat, Weronika, et al.
Publicado: (2019)

Using Proteomics Data to Identify Personalized Treatments in Multiple Myeloma: A Machine Learning Approach
por: Katsenou, Angeliki, et al.
Publicado: (2023)

Aminopeptidase N
por: Turner, Anthony J.
Publicado: (2013)

Metallo-aminopeptidase inhibitors
por: Mucha, Artur, et al.
Publicado: (2010)

Membrane alanyl aminopeptidase
por: Turner, Anthony J.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_bneq77roeami76fi96ihcles2p